Status:
TERMINATED
Effect of Sitagliptin on Graft Function Following Islet Transplantation
Lead Sponsor:
University of British Columbia
Collaborating Sponsors:
Merck Sharp & Dohme LLC
Conditions:
Islet Transplantation
Eligibility:
All Genders
20-65 years
Phase:
PHASE3
Brief Summary
Islet transplantation requires a large number of islets required to achieve insulin independence and the function of the transplanted islets progressively declines over time. Evidence from animal stud...
Detailed Description
Hypothesis: Sitagliptin taken for 12 months after an islet infusion will significantly improve islet function compared with a control group. Purpose: To determine if sitagliptin given at the time of ...
Eligibility Criteria
Inclusion
- Type 1 diabetes for \> 5 years with negative C peptide, GFR \> 70 ml/min, BMI ≤ 28 and non-smoker for ≥ 1 year
Exclusion
- Known hypersensitivity to sitagliptin
Key Trial Info
Start Date :
July 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
November 1 2013
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT00853944
Start Date
July 1 2009
End Date
November 1 2013
Last Update
October 30 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Vancouver General Hospital
Vancouver, British Columbia, Canada